$LTC

💡 Key developments driving

Reports indicate that MEI Pharma has completed a funding of $100 million, which is partially being allocated to an LTC retention strategy, a strong signal of institutional entry.

Increasing optimism about the possibility of approving an LTC exchange-traded fund (ETF) in the United States, supported by an anticipated "halving" event in August 2025 and technical updates in the network (LitVM Layer-2).

---

🎯 Technical and pivotal levels

Strong resistance: $116–119 (current area), and holding above this point may open the way toward the $130–140 area.

Immediate support: $102–105 (vital testing area for the current correction); below that, the price may drop to around $95–100.